## Supporting information.

	10 g run	40 g run
Artemisinin (g)	10.17 g	40.00 g
Artemisinin purity	99.6%	99.6%
Corrected artemisinin (g)	10.13 g	39.84 g
Solution yield DHA (g)	10.20 g	40.12 g
Isolated DHA (g)	9.41 g	35.97 g
Isolated DHA purity (%)	>99.9%	>99.9%
Theory (g)	10.20 g	40.12 g
Step Yield (%)	91.8%	89.7%
Loss to streams (g)	0.79 g	4.15 g
Loss to streams (%)	8.2%	10.3%
DHA starting mass (g)	9.41 g	35.9 g
Solution formation of <b>3</b> (g)	8.22 g	32.77 g
Solution formation of <b>4</b> (g)	0.84 g	3.43 g
Solution formation of 5 (g)	0.35 g	1.15 g
Crude Purity	98.7%	99.4%
Loss to crude streams <b>3</b> (g)	0.42 g	2.07 g
Yield loss <b>3</b> to crude streams	5.0%	4.9 %
Loss to crude streams 4 (g)	0.77 g	3.43 g
Loss to crude streams 5 (g)	0.27 g	1.21 g
Isolated Purity (%)	>99.9%	>99.9%
Isolated mass (g)	7.47	29.61 g
Theoretical mass (g)	10.70 g	42.10 g
Overall Yield (%)	69.8 %	70.3%
Crystallization loss 3 (g)	0.17 g	0.63 g
Crystallization loss <b>3</b> (%)	2.0%	1.5 %
Loss to final streams 4 (g)	0.07 g	0.06 g
4 in streams/ 4 formed	0.84 g/0.84 g	3.49 g/3.43 g
Loss to final streams 5 (g)	0.07 g	0.09 g
5 in streams/ 5 formed	0.34 g/ 0.35 g	1.30 g/1.21 g

Table 1: Yields and Process Stream Analysis for 10- and 40-g Runs

<u>HPLC Conditions for analyzing artemisinin starting material, monitoring conversion to 2</u> and evaluation of purity of 2 (a version of W.H.O. method)

Column: Eclipse XDB-C18, 15cm L X 0.46 cm ID, 5 μM particles, or equivalent Mobile phase: 50% acetonitrile/ 50% HPLC grade water Flow rate: 1.0 mL/min Run time: 15 minutes Detection: UV absorbance at 210 nm Injection: 20 μL Sample prep: Weigh 50 mg into 10 mL volumetric flasks as dissolve with mobile phase Retention times:

Hydrochloric acid:1.2 minutes $\alpha$ -dihydroartemisinin ( $2\alpha$ ):4.3 minutes $\beta$ -dihydroartemisinin ( $2\beta$ ):6.2 minutes9-epi-Artemisinin:6.8 minutesArtemisinin (1):7.6 minutes

HPLC Chromatogram of Mixture of 1 and 2











Formation of 7 occurs in solution as well as during drying. Depending on sample diluent, erroneously low purity assays in HPLC may result. Sample diluents described in the draft WHO monograph for dihydroartemisinin<sup>1</sup> do not take this into account. In methanol—as prescribed for purity assessment—7 forms at a rate of 0.6% per hour. This decomposition is sufficiently rapid to cause isolated pure 2 to fail its purity specification if not analyzed within 1 hour after dilution. Degradation is much faster (>12%/hour) in the acetonitrile/water diluent prescribed for assay. We find that dilution in neat acetonitrile greatly retards formation of 7.

## <u>Conditions for monitoring conversion of 2 to 3 and evaluation of purity of 3</u> (a version of W.H.O. method)

Column: Eclipse XDB-C18, 15cm L X 0.46 cm ID, 5 µM particles, or equivalent Mobile phase: 62% acetonitrile/ 38% HPLC grade water Flow rate: 1.0 mL/min Run time: 15 minutes Detection: UV absorbance at 210 nm Injection: 20 µL Retention times

Trimethylorthoformate:	1.6 minutes
$\alpha$ -dihydroartemisinin ( $2\alpha$ ):	2.8 minutes
$\beta$ -dihydroartemisinin ( <b>2</b> $\beta$ ):	3.7 minutes
$\alpha$ -artemether (4):	6.1 minutes
<b>5, 6</b> (putative)	7.2 minutes
$\beta$ -artemether ( <b>3</b> );	8.7 minutes

<sup>&</sup>lt;sup>1</sup> QAS/11.437 World Health Organization





Overlay of Chromatograms of crude (red) and pure (blue) **3.** The crude material contains impurities **4** and **5** present at 0.3% and 0.4%, respectively. These impurities are not detected in the recystallized product.

